Press Release: Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial Results

Dow Jones11-13
   -- Last patient, last visit of the 6-month treatment period in the Phase 3 
      DUET-AD study is scheduled for December 31, 2026, with database lock on 
      February 8, 2027, and data readout in March 2027 
 
   -- Parkinson's disease open-label extension (OLE-PD) study has enrolled 326 
      patients, with enrollment scheduled to close on January 29, 2027 
 
   -- Annovis raised $21.0 million in gross proceeds through an underwritten 
      public offering, which is expected to fund operations through the 6-month 
      data readout from DUET-AD 

MALVERN, Pa., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational oral therapy for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and reported financial results for the third quarter ended September 30, 2026.

"The third quarter marked a shift in our focus from enrolling patients in DUET-AD to executing the trial and preparing for the first data readout and for filing a New Drug Application (NDA)," said Maria Maccecchini, PhD, President and CEO of Annovis. "We now have dates set for last patient, last visit of the 6-month treatment period and for database lock, as well as financing in place to carry us through topline results in March 2027. The team is working very hard to deliver clean data and an on-time readout."

Clinical highlights

Alzheimer's disease -- DUET-AD

   -- Study description: The pivotal Phase 3 trial has been given the acronym 
      DUET-AD (Dual Efficacy Trial in Alzheimer's Disease), reflecting its 
      unique design with two prespecified data readouts -- at 6 months 
      (symptomatic) and at 18 months (disease-modifying). 
 
   -- Enrollment: DUET-AD is fully enrolled, with 862 patients who have early 
      AD (MMSE 20-28) and are positive for the plasma biomarker pTau217. 

Alzheimer's disease -- open-label extension (OLE-AD)

   -- Activation: The OLE-AD study will use the same clinical sites as DUET-AD. 
      The rollover of patients from DUET-AD into OLE-AD is expected to start by 
      the end of November 2026. 
 
   -- Eligibility: The OLE-AD study will allow patients from DUET-AD to receive 
      buntanetap after completing their 18-month treatment period. Patients 
      from both arms -- buntanetap and placebo -- will be allowed to join. The 
      OLE-AD study is also open to participants from Annovis' prior AD clinical 
      trials. 

Parkinson's disease -- open-label extension (OLE-PD)

   -- Enrollment: The OLE-PD study has enrolled 326 patients. It accepts 
      participants from Annovis' prior clinical trials as well as new patients 
      who have deep brain stimulation (DBS). 
 
   -- Study design: The OLE-PD study is designed to evaluate buntanetap's 
      safety and long-term efficacy over 36 months, supported by NeuroRPM, a 
      real-time digital biomarker that measures core PD symptoms, and a skin 
      biopsy test for alpha-synuclein pathology. 

Regulatory updates

   -- Weave Bio: In September, Annovis announced a partnership with Weave Bio, 
      an AI platform for regulatory content and knowledge management, to 
      support preparation of a planned NDA for buntanetap. The Company aims to 
      prepare a significant part of the NDA before the 6-month data readout 
      from DUET-AD. 

Corporate updates

   -- Financing: On November 6, 2026, Annovis closed an underwritten public 
      offering with gross proceeds of approximately $21.0 million. The Chairman 
      of the Board contributed $5.0 million as part of the offering. Details 
      can be found in the Company's SEC filings. 
 
   -- Webinar: Annovis hosted a corporate update webinar and live Q&A on 
      September 2, 2026, covering company progress, ongoing clinical programs, 
      and anticipated milestones. The recording is available online. 

Upcoming presentations

   -- CTAD 2026 (November 16-19, Boston): Annovis will deliver three 
      presentations at the 19th Clinical Trials on Alzheimer's Disease (CTAD) 
      conference: an oral presentation in the Biotech Showcase on targeting 
      proteostasis in AD, a poster on the design and baseline characteristics 
      of DUET-AD, and a poster on the use of AI for assessing blood-brain 
      barrier permeability of AD drug candidates. Details can be found in the 
      latest press release. 
 
   -- U.S. Biotech Day 2026 (November 16-17, Philadelphia): Dr. Maccecchini 
      will join a panel with leaders from Pfizer, Merck, Bristol Myers Squibb 
      and other pharmaceutical companies, and discuss the translational path of 
      bringing a small-molecule innovation from bench to late-stage clinical 
      development. 
 
   -- Pharma Partnering Summit (November 19-20, Boston): Dr. Maccecchini will 
      present a company update and hold one-on-one meetings. 

Upcoming milestones

   -- DUET-AD: Annovis expects last patient, last visit of the 6-month 
      treatment period on December 31, 2026, and database lock on February 8, 
      2027, with topline results in March 2027. This milestone defines the 
      6-month symptomatic analysis and does not mark the end of the study: 
      patients continue treatment for an additional 12 months to complete the 
      prespecified 18-month period of the study. The Company plans to present 
      the 6-month data at the AD/PD 2027 conference in Barcelona. 
 
   -- OLE-PD: Enrollment of new patients for the OLE-PD study is projected to 
      be completed by January 29, 2027. 

Financial results

   -- Annovis' cash and cash equivalents totaled $2.8 million as of September 
      30, 2026, compared to $19.5 million as of December 31, 2025. Annovis had 
      42.7 million shares of common stock outstanding as of September 30, 2026. 
 
   -- Research and development expenses for the three months ended September 
      30, 2026, were $15.8 million compared to $6.3 million for the three 
      months ended September 30, 2025. 
 
   -- General and administrative expenses for the three months ended September 
      30, 2026, were $1.2 million compared to $1.1 million for the three months 
      ended September 30, 2025. 
 
   -- Annovis reported a $0.22 basic and diluted net loss per common share for 
      the three months ended September 30, 2026, compared to a $0.37 basic and 
      diluted net loss per common share for the three months ended September 
      30, 2025. 

About Annovis

Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor Alerts

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.

Forward-Looking Statements

This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company's SEC filings under "Risk Factors" in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:

Annovis Bio Inc.

101 Lindenwood Drive

Suite 225

Malvern, PA 19355

www.annovisbio.com

Investor Contact:

Alexander Morin, PhD

Director, Strategic Communications

Annovis Bio

ir@annovisbio.com

 
Annovis Bio, Inc. 
 Balance Sheets 
 
                                    September 30, 
                                        2026        December 31, 
                                     (Unaudited)        2025 
 
Assets 
Current assets: 
  Cash and cash equivalents         $   2,819,898   $  19,532,338 
  Prepaid expenses and other 
   current assets                       2,683,829       1,549,287 
Total assets                        $   5,503,727   $  21,081,625 
                                     ============    ============ 
Liabilities and stockholders' 
(deficit) equity 
Current liabilities: 
  Accounts payable                  $   3,053,090   $   2,590,516 
  Accrued expenses                      3,211,462       1,044,859 
    Total current liabilities           6,264,552       3,635,375 
Non-current liabilities: 
    Warrant liability                  12,473,000         595,000 
    Total liabilities                  18,737,552       4,230,375 
                                     ------------    ------------ 
Commitments and contingencies 
(Note 6) 
Stockholders' (deficit) equity: 
  Preferred stock - $0.0001 par 
  value, 2,000,000 shares 
  authorized and 0 shares issued 
  and outstanding                              --              -- 
  Common stock - $0.0001 par 
   value, 70,000,000 shares 
   authorized, 42,686,201 and 
   27,199,139 shares issued and 
   outstanding at September 30, 
   2026 and December 31, 2025, 
   respectively                             4,268           2,719 
  Additional paid-in capital          192,354,899     180,552,190 
  Accumulated deficit                (205,592,992)   (163,703,659) 
    Total stockholders' (deficit) 
     equity                           (13,233,825)     16,851,250 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment